SAN DIEGO, May 28, 2025 /PRNewswire/ -- Transposon Therapeutics, a biotechnology company focused on developing novel, orally administered therapies for the treatment of neurodegenerative and ...
Treatment with TPN-101 showed clinical benefits on key clinical outcome measures, including the Revised ALS Functional Rating Scale (ALSFRS-R) and Slow Vital Capacity (SVC) TPN-101 also had lowering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback